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AbstrAct
Many glioblastoma patients suffer from seizures why they are treated with 
antiepileptic agents. Valproic acid (VPA) is a histone deacetylase inhibitor that apart 
from its anticonvulsive effects in some retrospective studies has been suggested to 
lead to a superior outcome of glioblastoma patients. However, the exact molecular 
effects of VPA treatment on glioblastoma cells have not yet been deciphered. We 
treated glioblastoma cells with VPA, recorded the functional effects of this treatment 
and performed a global and unbiased next generation sequencing study on the 
chromatin (ChIP) and RNA level. 1) VPA treatment clearly sensitized glioma cells 
to temozolomide: A protruding VPA-induced molecular feature in this context was 
the transcriptional upregulation/reexpression of numerous solute carrier (SLC) 
transporters that was also reflected by euchromatinization on the histone level and 
a reexpression of SLC transporters in human biopsy samples after VPA treatment. 
DNA repair genes were adversely reduced. 2) VPA treatment, however, also reduced 
cell proliferation in temozolomide-naive cells: On the molecular level in this context 
we observed a transcriptional upregulation/reexpression and euchromatinization of 
several glioblastoma relevant tumor suppressor genes and a reduction of stemness 
markers, while transcriptional subtype classification (mesenchymal/proneural) 
remained unaltered. Taken together, these findings argue for both temozolomide-
dependent and -independent effects of VPA. VPA might increase the uptake of 
temozolomide and simultaneously lead to a less malignant glioblastoma phenotype. 
From a mere molecular perspective these findings might indicate a surplus value of 
VPA in glioblastoma therapy and could therefore contribute an additional ratio for 
clinical decision making.
IntroductIon
Glioblastoma multiforme is the most common 
malignant brain tumor. The standard therapy consists of 
surgical removal and concomitant radiochemotherapy 
followed by adjuvant chemotherapy with temozolomide 
[1]. But despite this aggressive procedure, the prognosis 
remains poor. Since 20-50% of glioblastoma patients 
suffer from seizures [2], antiepileptic drugs (AEDs) are 
often administered alongside of chemotherapy and might 
influence the effect of the chemotherapeutic agent or exert 
direct chemotherapy-independent effects on the tumor 
itself.
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Valproic acid (VPA), for example, is an antiepileptic 
drug that is often used to treat seizures in glioblastoma 
patients. Interestingly, a number of retrospective analyses 
supported a disease course-modifying role of valproic acid 
in glioma patients [3-9]. As such also in the EORTC/NCIC 
temozolomide registration trial for glioblastoma, patients 
receiving VPA showed a prolonged survival over those 
receiving other (enzyme-inducing) or no AEDs. 
Several cell biological studies have investigated 
VPA effects on tumor cells in vitro. It could be 
demonstrated that VPA inhibits cell proliferation by 
causing cell-cycle arrest in the G1 and/or G2 phase and 
that it induces differentiation and/or apoptosis in cancer 
cells [10, 11]. Valproic acid also reduced proliferation rates 
in glioblastoma-derived stem cells [12] and decreased 
cell viability of primary human glioblastoma cells [13]. 
Furthermore, valproic acid was suggested to downregulate 
the expression of MGMT (O-6-methylguanine-DNA 
methyltransferase) and to sensitize human glioma cells to 
temozolomide and irradiation [14, 15]. 
Nevertheless, there is yet little systematic 
understanding of the exact VPA mode of action and 
-in particular- the molecular correlates associated with 
it. We thus treated a large cohort of classical adherent 
glioblastoma and primary glioblastoma stem cell lines 
with VPA, recorded the functional implications of this 
treatment and performed global and unbiased next 
generation sequencing (NGS) analysis on the RNA level. 
As VPA functions as a histone-deacetylase inhibitor 
(HDACi) and specifically inhibits HDAC classes I and IIa 
[16] we also performed chromatin immunoprecipitation 
followed by NGS (ChIP-Seq) comparing VPA-naive with 
VPA-treated glioblastoma cells. We thus aimed to decipher 
how VPA alters the epigenetic decor of the tumor cells.
Despite a recent metaanalysis of prospective clinical 
trials that could not confirm a beneficial effect of VPA 
on outcome in newly diagnosed glioblastoma patients 
[17], there is currently an ongoing debate on whether the 
putative beneficial VPA effects in glioblastoma should 
be tested in a prospective randomized clinical trial [18]. 
Our study may inform on the drug’s mode of action in 
glioblastoma cells and thereby provide an additional 
molecular ratio for clinical decision making. 
Figure 1: VPA causes sensitization to temozolomide and reduced proliferation. (a, b, c) Valproic acid leads to a sensitization 
to temozolomide in seven adherent and four stem cell lines. Shown is the relative reduction of IC50 values (*p<0.05 in at least one 
experiment) after VPA treatment (c) which results in a shift of the temozolomide response curves to the left, exemplarily shown for 
U118MG (a) and NCH421k (b). (d) Valproic acid also leads to (significantly) reduced proliferation rates in most of the analyzed cell lines. 
*p<0.05, **p<0.01; two-tailed t-test. Results were reproduced in a second independent experiment. 
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results
Valproic acid sensitizes glioma cell lines to 
temozolomide and decreases proliferation
First, we aimed to investigate the functional 
implications of VPA treatment on glioma cells. We 
therefore treated the six established glioblastoma cell 
lines and HS683 with VPA and subsequently performed 
temozolomide chemosensitivity assays. All seven cell 
lines were sensitized to temozolomide (Figure 1a, 1c). 
Five cell lines (TP365MG, U118MG, U251MG, U373MG 
and HS683) even showed a statistically significant VPA-
induced reduction (p<0.05) of their IC50 values. 
We then subjected the seven glioblastoma stem cell 
lines to identical experimental conditions. However, three 
of the lines, i.e. NCH1425, NCH601 and NCH636, were 
not suited for functional assays due to the fact that they 
were very sensitive to dissociation procedures necessary 
for cell counting and seeding. Hence, they were omitted 
from the experiment. In the four remaining stem cell lines 
that could be tested, we observed a similar sensitization to 
temozolomide after VPA treatment as for the established 
glioma cell lines (Figure 1b, 1c). 
We next wanted to know whether VPA treatment 
would have effects on tumor cell proliferation also 
irrespectively of temozolomide in a chemotherapy-
naive situation. Indeed, in the broad majority of the 
investigated cell lines (with exception of NCH421k, 
NCH465 and NCH660h) VPA treatment significantly 
reduced proliferation (two-tailed t-test: p<0.05 or <0.01, 
respectively; Figure 1d). 
unbiased bioinformatical analysis suggests 
activation of multiple slc transporters as a main 
molecular correlate of VPA response 
In order to gain insight into the molecular correlates 
of the VPA effect on human glioma cells we analyzed 
all 14 cell lines before and after treatment with valproic 
acid by RNA-Seq and ChIP-Seq. Using RNA-Seq, we 
performed principal component analysis (PCA) based 
on the RPKM (reads per kilobase per million mapped 
Figure 2: bioinformatical analyses of VPA response 
signatures. (a) Principal component analysis (PCA) reveals 
that VPA similarly affects gene expression in all investigated cell 
lines by a shift on the PC2 axis (indicated by the arrows). The PC1 
axis segregates cancer stem cells from adherent glioblastoma cell 
lines. The stem cell line NCH1425 maps relatively close to the 
adherent cell lines which reflects the fact that -instead of typical 
sphere formation- this cell line exhibits a more adherent growth 
mode than the other stem cell lines. (b) GO term analysis with 
the 497 gene list (upregulated in ≥4 out of 7 adherent and ≥4 out 
of 7 glioblastoma stem cell lines, p<0.01, FC ≥5) demonstrates 
significant enrichment of several GO terms containing the term 
“transport” (p<0.1). (c) SLC transporters both with significantly 
enhanced H3ac-promoter-binding and significant transcriptional 
upregulation (≥4 out of the 7 adherent and ≥4 out of the 7 
glioblastoma stem cell lines, p<0.01). Transporters are listed by 
fold change differences (FC ≥5, FC ≥4, FC ≥3, FC ≥2) according 
to RNA-Seq. (d) Gene set enrichment analysis confirms the 
upregulation of SLC transporters and additionally discloses a 
downregulation of different groups of DNA repair genes (double 
strand break repair, mismatch repair, base excision repair and 
nucleotide excision repair). For exact definition of gene sets 
compare Table S4. NP = normalized p-value, FC = fold change, 
NES = normalized enrichment score, FDR = false discovery rate.
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reads) values of the sequenced samples (Figure 2a). 
Samples on the PC1 axis were separated by cell type 
(i.e. established adherent vs. stem cell lines). On the 
PC2 axis, samples were separated by whether they had 
received VPA treatment or not. Of note, VPA treatment 
shifted all cell lines in the same direction irrespective of 
whether they were adherent or stem cell lines arguing for 
concordant molecular VPA effects in both cell types. We 
then analyzed the transcriptome data from all cell lines 
by performing a pairwise comparison (VPA-treated versus 
untreated) for each individual cell line using the Audic-
Claverie algorithm [19]. This led to the identification 
of a few thousand upregulated genes in each single cell 
line (adjusted p<0.01; Table S2). ChIP-Seq analysis 
revealed a few hundred thousand regions per cell line 
(enriched regions, p<0.01; Table S2) that had an increase 
of acetylated histone H3. These still corresponded to a 
few ten thousand euchromatinized regions with promoter 
correlation (-1000 to 0 relative to transcription start site). 
To further narrow down the number of target genes we 
analyzed all 14 cell lines and not only allowed for the 
detection of genes that were upregulated in all cell lines 
but also in the majority (at least 4 out of 7) of both the 
adherent and the stem cell lines. Applying the most 
conservative fold change cut-off (≥5), on RNA-Seq 497 
genes met these criteria (Table S2). 
This 497-gene expression signature was then 
subjected to GO term analyses. GO terms containing 
the designation “transport” were most prominently 
enriched (six different GO terms, adjusted p<0.1 each, 
Benjamini corrected, Figure 2b) and within these GO 
terms SLC transporters were the most prominent group 
of genes. SLC transporters were significantly enriched 
in the 497-gene list (16 transporters) as compared to 
the whole genome (46,111 genes, 397 SLC transporters; 
Fisher’s exact test: p=1.18 E-5). 4 out of the 16 
transporters were also epigenetically altered by promoter 
euchromatinization. The number of both epigenetically 
altered (euchromatinized) and overexpressed transporters 
increased with choosing less conservative fold change cut-
offs (4 at ≥5, 6 at ≥4, 8 at ≥3, 16 at ≥2, Table S2, Figure 
2c). Gene set enrichment analysis (GSEA) was then used 
to confirm the enrichment of the 16 SLC transporters 
that at fold change ≥2 were both overexpressed and 
epigenetically altered in our VPA-response signatures 
(normalized p<0.05) (Figure 2d).
Validation of upregulation of slc transporters 
in glioma cells and human patient biopsy samples 
after VPA treatment
We performed real-time RT-PCR analyses to 
validate the reexpression of SLC transporters in our glioma 
cell lines after VPA treatment. We exemplarily analyzed 
the four transporters (SLC17A7, SLC25A27, SLC30A3 
and SLC6A12) that were upregulated on the mRNA level 
with the highest fold change (≥5) and had concomitant 
promoter euchromatinization on ChIP-Seq. All four 
transporters after VPA treatment were overexpressed in 
Figure 3: Immunohistochemistry states reactivation 
of slc transporter expression in patients’ biopsy 
samples under VPA treatment. SLC transporters are 
weakly expressed in non-neoplastic brain tissue with SLC17A7 
(a) a little stronger than SLC25A27 (b). c/d, e/f, g/h, i/j; matched 
pairs of biopsy samples from individual patients before (c, e, 
g, i) and under (d, f, h, j) valproic acid treatment. c/d shows 
immunohistochemistry for SLC17A7, while e/f, g/h and i/j 
show immunohistochemistry for SLC25A27. Note that there 
is a clear increase in SLC transporter expression in the biopsy 
samples following valproic acid treatment. These effects were 
more consistently (higher fraction of patients) observed for 
SLC25A27.
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Figure 4: Functional effects of sirnA-mediated slc transporter knockdown. U373MG cells were transfected with siRNAs 
against 16 different SLC transporters and analyzed for proliferation using the Resazurin assay. (a) VPA and temozolomide treatment: The 
effect of siRNA-mediated SLC transporter knockdown on the temozolomide response was compared between VPA-treated and VPA-naive 
cells (relative proliferation difference between VPA-treated and VPA-naive siCTRL cells set to 1). For the knockdown of single transporters 
(such as SLC30A3) there was a weak functional reversal of the VPA effect corresponding to a relative TMZ desensitization under VPA. (b) 
Temozolomide treatment only: When assessing the temozolomide response independently of VPA, the knockdown for a higher number of 
transporters led to a slightly enhanced relative proliferation corresponding to temozolomide desensitization (relative proliferation between 
temozolomide-treated and temozolomide-naive siCTRL cells set to 1). (c) Neither VPA nor temozolomide treatment: There were no major 
direct effects of SLC transporter knockdown on tumor cell proliferation itself. *p<0.05, two-tailed t-test.
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the majority of cell lines, partly up to more than 100-fold 
(Figure S1).
For two of the transporters (SLC17A7 and 
SCL25A27) antibodies were available that worked in 
formalin-fixed paraffin-embedded tissue. We stained 
matched pairs of patient biopsy samples (n=6) that 
allowed for the comparison of SLC transporter expression 
prior and after VPA treatment. Indeed, for SLC17A7 we 
detected a reexpression in three out of six patients (one 
clear and two moderate increases, Table S3, Figure 3c,3d). 
For SLC25A27, four out of six patients had an obvious 
reexpression. While in five patients the second biopsy 
was taken directly under VPA treatment, patient 4 was 
biopsied for the second time three years after VPA had 
been discontinued. Thus, in fact four out of five patients 
showed an increase in SLC25A27 expression after the 
drug’s application (Table S3, Figure 3e-j). Interestingly 
in this context, in non-neoplastic brain tissue SLC17A7 
was expressed stronger than SLC25A27 (Figure 3a, 3b). 
These higher basal expression levels of SLC17A17 might 
explain for the fact that VPA-induced upregulation for this 
transporter was not as strongly and clearly visible as for 
SLC25A27. 
Functional implications of altered slc 
transporter expression on glioma cells
We reasoned that if the overexpression of SLC 
transporters should account for the sensitization of 
VPA-treated cells to temozolomide, siRNA knockdown 
of SLC transporters should rescue the VPA-induced 
chemosensitization. We therefore performed siRNA 
knockdown experiments with the 16 transporters (Figure 
2c) that were upregulated and euchromatinized following 
VPA treatment. 
VPA-pretreated and -naive U373MG cells were 
transfected with the respective siRNAs or negative 
control siRNA. Then, temozolomide was applied in 
concentrations (1,500 µM) close to the expected IC50 
doses. We first calculated the extent of VPA-induced 
sensitization in response to temozolomide (relative 
reduction of proliferation by temozolomide in the VPA-
treated cells compared to the VPA-naive cells) for the 
siCTRL transfection and set this to 1. We then assessed 
the VPA-induced effects in response to temozolomide 
with the respective targeting siRNAs and normalized 
them to siCTRL. If for a defined siRNA the VPA-induced 
temozolomide sensitization was stronger compared to 
siCTRL this would lead to a relative proliferation value 
of <1 indicating an additional sensitization induced by the 
siRNA knockdown. If the VPA-induced temozolomide 
sensitization in the context of a defined siRNA was weaker 
compared to siRNA control this would lead to a relative 
proliferation value >1 indicating a desensitization by the 
respective siRNA knockdown and thus the presumed 
rescue effect (Figure 4a). Here, for the knockdown of 
single transporters (such as SLC30A3) we observed a 
weak functional reversal of the VPA effect. Nevertheless, 
the observed effects did not appear strong and consistent 
Figure 5: Gene-expression based molecular 
classification of the cell lines remains unchanged after 
VPA treatment. Following VPA treatment, we observed a 
statistically significant enrichment (p=0.03) of mesenchymal 
signature genes in the glioblastoma stem cell lines (a), while 
in the adherent glioblastoma cell lines there was a statistically 
significant enrichment (p=0.02) of proneural signature genes 
(b). Nevertheless, VPA treatment did not change molecular 
subtype classification with the stem cell lines retaining the 
proneural and the adherent cell lines retaining the mesenchymal 
expression subtype as the prevailing one (c). *p<0.05, Wilcoxon 
signed rank test.
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enough to fulfill the criteria of a successful rescue 
experiment. 
Since this rather complex experimental setting 
did not allow for detecting a clear rescue effect we next 
wanted to know whether the SLC transporter knockdown 
in a situation uninfluenced by VPA would lead to 
temozolomide desensitization. This would be indicative 
for the transporters being involved in the uptake of 
temozolomide. Here, results were still rather inconsistent 
but knockdown for a higher number of transporters led to 
a slightly enhanced relative proliferation (temozolomide-
treated versus temozolomide-naive, siCTRL set to 1; 
Figure 4b). This, particularly in consideration of the fact 
that SLC transporter knockdown did not have major direct 
effects on tumor cell proliferation itself (Figure 4c), might 
provide subtle indications for a relevance of individual 
SLC transporters in the VPA-mediated temozolomide 
response. In the discussion section we will further 
comment on the experimental limitations that may have 
impeded a higher clearness of the results. 
other molecular factors that might explain for 
a better temozolomide response under VPA 
treatment 
As MGMT had been linked to the VPA response 
[14], we assessed VPA-induced changes of MGMT 
expression, promoter methylation and promoter 
euchromatinization in our cell lines (Table 1a). Except 
for a significant upregulation (p<0.01) in one single cell 
line (NCH660h), mRNA expression after VPA treatment 
was largely unaffected. For MGMT promoter methylation 
only TP365MG showed a moderate increase (74 to 94%) 
after VPA treatment. H3ac binding to the MGMT promoter 
was significantly increased (p<0.01) in six cell lines but 
this cannot explain for temozolomide sensitization. Taken 
together, these findings do not argue for a major relevance 
of MGMT in the VPA response.
Apart from upregulation of SLC transporters, 
GSEA also pointed towards a downregulation of DNA 
repair genes after VPA treatment (Figure 2d; Table S4). 
Euchromatinization of inhibitors of DNA repair genes 
could be a possible explanation for this phenomenon. We 
therefore analyzed in further detail the most important 
genes of the three functional groups “mismatch repair” 
(MMR), “base excision repair” (BER) and “double-strand 
break repair” (DSB repair) [20] (Table 1b). Within the 
group of base excision repair genes, PARP2 and PARP3 
were most frequently downregulated by VPA treatment 
since they showed a significant downregulation (p<0.01) 
in ten and eleven out of the 14 cell lines, respectively. 
Amongst the double-strand break repair genes, NBN and 
RAD51 exhibited a significant downregulation in the 
majority of cell lines (nine and eleven lines, respectively). 
The expression of mismatch repair genes in comparison 
(except for MLH1) was downregulated in much lower 
frequencies in only individual cell lines.
Molecular correlates for potential beneficial 
temozolomide-independent VPA effects on glioma 
cells
As indicated above (Figure 1d) we also observed 
a direct chemotherapy-independent negative effect of 
VPA on the proliferation of glioma cells. Thus, aside 
from molecular alterations that might explain for a 
chemosensitization of glioma cells we analyzed our 
signatures for molecular alterations that might explain 
for a therapy-independent “benignization” of the tumor 
genotype. We first analyzed a set of the most common 
tumor suppressor genes for transcriptional upregulation 
and promoter euchromatinization after VPA treatment 
(Table 1c). Indeed, almost all cell lines, with the exception 
of NCH465, exhibited reexpression of at least one tumor 
suppressor arguing for a relevance of tumor suppressor 
upregulation in the VPA effect. Two genes, namely 
CDKN1A (p21) and SFRP1 appeared to be majorly 
affected, showing significant upregulation (p<0.01) in 
eight cell lines, respectively. Reexpression of CDKN1A 
was validated by q-RT-PCR analyses (Figure S2). 
Promoter euchromatinization was also observed for the 
majority of the genes and was even more frequent than 
transcriptional reexpression. 
We next wanted to know whether VPA treatment 
would reduce the expression of classical stem cell markers 
such as CD44, CD133, Nestin, OCT3/4 and SOX2 (Table 
1d). Indeed, we found a significant downregulation 
(p<0.01, Audic-Claverie algorithm) of stem cell markers 
(in particular CD44 and CD133) in a number of cell 
lines. Unsurprisingly, in general, the reduction was more 
frequently observed in the stem cell lines arguing for a 
differentiation-inducing effect of VPA.
Finally, we investigated whether VPA treatment 
would change gene-expression based molecular 
classification of glioma cell lines (either mesenchymal or 
proneural) [21]. According to this classification all of our 
adherent glioma cell lines belong to the mesenchymal and 
all of our glioma stem cell lines (except for NCH1425) to 
the proneural expression subgroup. After VPA treatment 
the stem cell lines showed a significant enrichment of 
signature genes related to the mesenchymal subtype 
(Figure 5a; Wilcoxon signed rank test: p=0.03) while 
the adherent cell lines had a significant enrichment of 
proneural signature genes (Figure 5b; Wilcoxon signed 
rank test: p=0.02). This, however, did not change subtype 
classification of the respective cell lines. In the adherent 
cell lines the mesenchymal expression signature and in 
the stem cell lines the proneural expression signature 
still prevailed (Figure 5c). Thus, VPA treatment causes 
a general enrichment (particularly of weakly expressed) 
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table 1: synopsis of the different types of genes affected in their transcription or H3ac-promoter 
dnA binding levels by VPA treatment. 
MGMT (a) was investigated for overexpression, increase in methylation and euchromatinization; DNA repair genes (b) and 
stem cell markers (d) were investigated for transcriptional downregulation; and tumor suppressor genes were investigated 
for euchromatinization and transcriptional upregulation. Blue indicates that a gene is significantly downregulated and dark 
red that a gene is significantly upregulated on the mRNA level (fold change ≥2, p<0.01). Light red additionally highlights 
genes that are upregulated (fold change ≥2) but do not reach significance. Horizontal stripes indicate an increase in promoter 
methylation whereas vertical stripes indicate significant (p<0.01) promoter euchromatinization induced by VPA. Note that 
MGMT is rather activated than inactivated by VPA. Other DNA damage repair genes and stem cell markers are commonly 
reduced (b and d), while a number of established tumor suppressor genes gets euchromatinized and reexpressed by VPA (c). 
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subtype-related signature genes but in its overall effects 
does not change the gene-expression based molecular 
classification. 
dIscussIon
VPA, an antiepileptic drug used to treat seizures 
in brain-tumor patients, has been suggested to have anti-
cancer effects but its exact molecular modes of action have 
not yet been deciphered. VPA is also a histone-deacetylase 
inhibitor [16]. We therefore investigated the molecular 
correlates of the VPA effect in glioma cells by using a 
comprehensive and unbiased genome-wide approach 
combining RNA-Seq and ChIP-Seq analyses.
First, we assessed the functional implications of 
VPA treatment on our cell lines. Indeed, in all lines studied 
VPA treatment sensitized glioma cells to temozolomide. 
This finding for adherent glioma cell lines had been 
reported in a similar fashion in a number of preceding in 
vitro studies [14, 15], but not for glioma stem-like cells. 
Comparing the molecular profiles before and after 
VPA treatment we found that GO terms with the functional 
annotation “transport” were associated with the VPA 
response signature. Indeed, numerous SLC transporters 
were transcriptionally upregulated and euchromatinized 
following VPA treatment. The solute carrier (SLC) group 
of membrane transporters comprises a family of more than 
300 membrane-bound transporters [22]. SLC transporters 
have also been shown to mediate the influx of cytotoxic 
drugs into cells [23] thereby increasing the intracellular 
drug concentrations. Also, they have been implicated 
in transporting anticancer drugs across the blood-brain-
barrier [24]. Strikingly, when investigating matched patient 
biopsy tissue samples before and under VPA treatment we 
observed an increase of SLC transporters (SLC17A7 and 
SLC25A27) in most of the patients analyzed. 
Given this apparent association between VPA-
induced chemosensitization and SLC transporter 
upregulation we followed up functionally on these 
relationships. We first aimed to rescue the VPA-
induced chemosensitization by siRNA-mediated 
transporter knockdown. Though leading to a moderate 
chemodesensitization for individual transporters these 
effects did not appear convincingly strong and consistent 
(Figure 4a). However, in a situation uninfluenced by 
VPA SLC transporter knockdown in a higher number of 
cell lines led to a slight chemodesensitization (Figure 
4b) and SLC transporter knockdown did not appear to 
exert major direct effects on tumor cell proliferation 
itself (Figure 4c). Thus, overall these experiments might 
provide subtle indications for a role of SLC transporters 
in the temozolomide response. The potential causes 
that obscure more explicit effects are manifold: Firstly, 
as there are more than 300 different SLC transporters 
with overlapping function, the knockdown of a single 
transporter might simply not be sufficient to induce the 
desired effects. Secondly, though the siRNAs themselves 
had reasonable knockdown efficiencies (Figure S3a), the 
high SLC transporter expression increase induced by 
VPA might not have been restored to VPA-naive levels 
by siRNA treatment (Figure S3b). Functional responses 
would hence also be limited after siRNA treatment. 
Finally, temozolomide is known as a substance that due 
to its lipophilic properties and its relatively small size 
[25] can easily cross the blood-brain-barrier and also for 
intracellular uptake might not alone depend on uptake 
transporters like the SLCs.
As others had shown that VPA downregulated the 
expression of MGMT [14] and this could serve as an 
explanation for VPA-induced chemosensitization, we also 
explored this possibility. MGMT expression and promoter 
methylation were hardly altered by VPA treatment and the 
MGMT euchromatinization we observed could not explain 
for temozolomide sensitization. Taken together, our 
analyses do not support a major relevance of MGMT as 
mediator of the observed VPA response. In glioblastoma 
patients, however, also DNA repair mechanisms other than 
MGMT may modify the temozolomide response [20]. Of 
note, we detected a downregulation of BER and DSB 
repair genes as a common mechanism in a larger number 
of cell lines. Disruption of the whole BER mechanism 
and, in particular, downregulation of APEX1 has been 
reported to enhance the cytotoxic effects of temozolomide 
[26, 27]. Also, PARP inhibitors have long been discussed 
for the treatment of glioblastoma patients [28, 29]. 
Inactivation of the DSB repair gene NBN resulted in a 
sensitization to temozolomide in melanoma cells [30] and 
the downregulation of RAD51 induced a temozolomide 
sensitizing effect in glioma cells [31]. We found all 
these genes downregulated after VPA treatment (Table 
1b). Downregulation of MMR genes, such as MSH2 and 
MSH6, has been described to evolve under therapy with 
alkylating agents and would rather mediate opposite 
effects, i.e. temozolomide resistance [32, 33]. These 
genes (except for MLH1), however, were only reduced in 
individual cell lines.
Our functional analyses revealed that VPA treatment 
had also direct (temozolomide-independent) effects on 
tumor cell proliferation. A molecular correlate that might 
explain for this finding was the euchromatinization and 
upregulation of various well-established tumor suppressor 
genes, with CDKN1A (p21) and SFRP1 being the most 
frequently upregulated genes on the mRNA level. 
The finding of CDKN1A reexpression is in line with a 
preceding publication that describes upregulation of this 
gene after VPA treatment [34]. SFRP1 encodes a WNT 
inhibitor the expression of which has been shown to be 
of positive prognostic relevance in gliomas [35]. Both 
genes are also known to be epigenetically regulated in 
gliomas. VPA in this way might ameliorate the biological 
characteristics of glioma cells, inducing a benignization 
of glioma genotypes. VPA, particularly in the stem cell 
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lines, also diminished the expression of classical stem 
cell markers (CD44, CD133) thus inducing a potential 
differentiation of glioma genotypes which is in line with a 
previous publication [12]. 
In summary, we here present a comprehensive 
molecular next generation sequencing study deciphering 
the global molecular VPA effects on the epigenetic 
(histone) and transcriptional level. We find that the VPA 
effects are manifold including molecular alterations that 
might directly enhance the temozolomide response and 
others that might induce temozolomide-independent 
favorable effects on glioma biology. Thus, our study 
from a molecular point of view highlights potential anti-
tumorigenic modes of action of VPA in glioma cells. 
The question remains whether this also translates into 
relevant clinical effects as a very recent pooled analysis of 
prospective clinical trials (retrospective in nature in respect 
to VPA though) could not retrace an association between 
VPA use and improved survival outcomes in patients 
with newly diagnosed glioblastoma [17]. Factors that 
might impede a 1:1 translation of molecular into clinical 
effects are the multitude of molecular changes observed. 
We pointed out that on the level of each single cell line a 
few ten thousand euchromatinized regions with promoter 
correlation and a few thousand upregulated genes were 
observed (Table S2). As it is impossible to assess these 
alterations in their entirety, we concentrated on genes 
overlappingly regulated between cell lines. However, 
we cannot exclude that in individual cell lines/patients 
molecular changes might be effective that dilute the overall 
favorable response signatures explicated in our study (for 
example see our comment on the downregulation of MMR 
genes above). Also, in the framework of our work we 
were not able to cover additional pharmacokinetic effects 
that might modify VPA effects. In this regard, it has been 
reported, e.g., that VPA leads to a decreased oral clearance 
of temozolomide of about 5% [36].
In case a prospective randomized controlled 
clinical trial on the use of VPA in glioblastomas should 
still be intended, our analyses reveal that there a) will 
be no simple molecular read-out that could be used for 
stratification or an upfront identification of patients most 
likely to benefit from standard therapy plus VPA and that 
b) also the underlying molecular set-up of the individual 
patient may well influence the response towards the agent. 
For the study design it thus would be the challenge to best 
possibly control for such underlying molecular factors and 
to keep patient groups as homogeneous as possible. 
MAterIAls And MetHods
cell lines and valproic acid (VPA) treatment
Six established adherent glioblastoma cell lines 
(T98G, TP365MG, U87MG, U118MG, U251MG and 
U373MG) and HS683 (derived from an anaplastic 
oligodendroglioma) were cultured under standard 
conditions (37°C, 5% CO2, DMEM, 10% FCS, 1% 
penicillin/streptomycin). In addition, seven human 
primary stem cell-like glioblastoma cell lines (NCH1425, 
NCH421k, NCH465, NCH601, NCH636, NCH644, 
NCH660h) [37], all of which were kindly provided by 
Professor Christel Herold-Mende (Dept. of Neurosurgery, 
Heidelberg University Hospital), were cultured under the 
following conditions: 37°C, 5% CO2, DMEM/Ham’s F-12 
medium, 1% penicillin/streptomycin, 1% L-glutamine. 
Directly before use, stem cell medium was prepared 
freshly by adding 20% BIT admixture supplement (Pelo 
Biotech, Planegg, Germany), 0.02% epidermal growth 
factor (EGF) (ReliaTech, Wolfenbuettel, Germany) 
and 0.02% basic fibroblast growth factor 2 (bFGF2) 
(ReliaTech). Valproic acid sodium salt (Sigma Aldrich, 
St. Louis, MO, USA) was dissolved in distilled water and 
subsequently diluted freshly in complete DMEM. Cells 
were treated with 7.5 mM VPA [38] for 36 h [39]. Origin 
of the cells was confirmed by short tandem repeat profiling 
prior to use either compared to known profiles (adherent 
cell lines) or to the original patient tissue (stem cell lines).
rnA extraction and real-time reverse 
transcription (rt) Pcr analysis
The RNeasy Plus Mini Kit (Qiagen, Hilden, 
Germany) was used according to the manufacturer’s 
protocol to extract RNA from untreated and VPA-
treated cells, respectively. Subsequent cDNA synthesis 
from one microgram total RNA was performed using 
random hexamer primers (Gene Link, Hawthorne, NY, 
USA) and the SuperScriptTM II Reverse Transcriptase 
(Life Technologies, Carlsbad, CA, USA). Expression 
of candidate gene transcripts was validated by real-time 
quantitative RT-PCR based on the SensiFASTTM SYBR Hi-
Rox Kit (Bioline, London, UK) with the StepOnePlusTM 
sequence detection system (Life Technologies). Fold 
expression changes relative to non-neoplastic brain tissue 
were calculated with the ΔΔCT method [40] using GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase) as the 
reference transcript (primer sequences: Table S1).
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chromatin immunoprecipitation (chIP)
For chromatin immunoprecipitation 106 cells 
(untreated and VPA-treated, respectively) were incubated 
with 1% formaldehyde (Roth, Karlsruhe, Germany) for 10 
minutes to cross-link the DNA with proteins. Afterwards, 
cells were resuspended in freshly prepared swelling 
buffer. Isolated nuclei were then further processed 
using a commercial ChIP assay kit (Merck Millipore, 
Darmstadt, Germany) following the manufacturer’s 
recommendations. After resuspension in SDS lysis buffer, 
lysates were sonicated with an ultra-sonicator (Covaris, 
Woburn, MA, USA) to shear the DNA into 200-800 bp 
fragments. Sonication was followed by centrifugation 
and samples were diluted in ChIP dilution buffer and 
precleared with salmon sperm DNA/protein A agarose 
beads. Immunoprecipitation with antibodies against 
acetylated histone H3 (H3ac) was performed overnight at 
4°C, rabbit anti-human IgG fraction served as a negative 
control. Then, the antibody-histone-DNA complexes 
were collected and histone-DNA complexes were eluted 
in freshly prepared elution buffer. After reversion of the 
cross-link, the DNA was recovered by phenol/chloroform 
extraction and ethanol precipitation. 
next-generation sequencing (nGs)
H3ac-immunoprecipitated DNA from untreated and 
treated cells was used to generate libraries for NGS using 
the TruSeq® ChIP Sample Preparation Kit (Illumina, 
San Diego, CA, USA) according to the manufacturer’s 
instructions. Isolated RNA from untreated and VPA-
treated cells was converted into libraries of template 
molecules suitable for NGS using the TruSeq® RNA 
Sample Preparation Kit v2 (Illumina). All libraries were 
quantified using the KAPA SYBR FAST ABI Prism 
Library Quantification Kit (Kapa Biosystems, Woburn, 
MA, USA). Equimolar amounts of each library were 
used for cluster generation on the cBot with the TruSeq 
SR Cluster Kit v3 (Illumina). The sequencing run was 
performed on a HiSeq 1000 instrument (Illumina) using 
the indexed, 50 cycles single read (SR) protocol and the 
TruSeq SBS v3 Kit (Illumina). Image analysis and base 
calling resulted in .bcl files which were then converted 
into .fastq files by the CASAVA1.8.2 software. Analysis 
of NGS data was performed using the Genomatix software 
(Genomatix, Munich, Germany). First, the .fastq files were 
mapped to the human genome hg19 (annotation based on 
ElDorado 12-2012) using the Genomatix Mining Station. 
Then, all unique hits were further processed using the 
Genomatix Genome Analyzer (Expression Analysis tool 
for RNA-Seq; ChIP-Seq Workflow and GenomeInspector 
tool [41] to identify significantly enriched promoter 
regions; List comparison tool to identify overlapping hits 
from RNA-Seq and ChIP-Seq analyses).
bioinformatical analyses using online 
bioinformatics resources
Principal component analysis (PCA) was based on 
the top 1,800 most variable genes that were calculated from 
the RPKM (reads per kilobase per million mapped reads) 
expression values. A biplot was then created with custom 
R scripts and the package ggbiplot. GO term analysis was 
performed using the DAVID (database for annotation, 
visualization and integrated discovery) bioinformatics 
resources as described elsewhere [42] and a corrected 
enrichment p-value for each GO term was calculated. 
Gene set enrichment analysis (GSEA; URL: http://www.
broadinstitute.org/cancer/software/genepattern) was 
performed in order to determine whether a priori defined 
sets of genes were over- or underrepresented in our gene 
expression signatures. Glioblastoma signature genes were 
taken from [21].
temozolomide chemosensitivity assay and 
quantification of MGMT promoter methylation
Cells were seeded in triplicates in 96-well plates at 
a density of 500 cells in 100 µl per well. 24 h later, the 
medium was replaced by fresh medium with or without 
7.5 mM valproic acid, respectively. After another 24 
h, various concentrations of temozolomide (1–8,000 
µM) were added. Cell viability was measured 72 h 
later using resazurin (R&D Systems, Minneapolis, MN, 
USA) as described elsewhere [43-45]. The half maximal 
inhibitory concentration (IC50) value was determined as 
the concentration resulting in a 50% growth reduction 
compared to control cell growth (i.e. cells that did 
not obtain temozolomide). Statistical analyses were 
performed using the GraphPad Prism software (version 6). 
Fluorescence intensities were log-transformed, normalized 
and then fitted with the methods of least squares and 
variable slope. 
Methylation of MGMT promoter DNA from 
untreated and VPA-treated samples was assessed via 
MethyQESD (methylation-quantification of endonuclease-
resistant DNA) as described before [46].
sirnA transfections
Transfections with small interfering RNAs were 
performed using the DharmaFECTTM transfection 
reagent (GE Healthcare Dharmacon, Freiburg, Germany) 
according to the manufacturer’s protocol. Cells were 
seeded in triplicates in 96-well plates at a density of 
3,000 cells in 100 µl per well. 24 h later, half of the cells 
were treated with 7.5 mM VPA for 24 h. Then, 25 nM 
of siRNAs were transfected in medium with or without 
valproic acid, respectively. The next day, temozolomide at 
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a concentration of 1,500 µM was added and cell viability 
was measured 72 h later via the resazurin assay. 
Immunohistochemistry
Matched pairs of formalin-fixed and paraffin-
embedded tissue samples from brain tumor patients 
before and after VPA treatment were selected from the 
tumor tissue archive of the Regensburg Department 
of Neuropathology and investigated according to 
protocols approved by the institutional review board. 
Immunohistochemical staining was performed following 
a standard protocol [35]. Briefly, 4-µm sections were cut, 
slides were deparaffinized and, after sodium citrate buffer 
antigen retrieval and blocking, incubated with the primary 
antibody for 45 minutes. As primary antibodies, we used 
anti-SLC17A7 and anti-SLC25A27 (both from Origene, 
Rockville, MD, USA). The EnVisionTM+ Dual Link 
System-HRP (Dako by Agilent Technologies,  Santa Clara, 
CA, USA) was used for detection of antibody binding 
according to the manufacturer’s protocol. Afterwards, 
nuclei in the immunostained sections were counterstained 
with haematoxylin. 
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